Hepatitis B Virus/Hepatitis D Virus–Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid–Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. Issue 5 (12th May 2021)

• Record Type: Journal Article
• Authors: Hammami, Muhammad Baraa; Kohli, Ruhail; Woreta, Tinsay; Sulkowski, Mark S.; Hamilton, James P.; Toman, Lindsey; Saberi, Behnam; Laurin, Jacqueline; Wang, Jacqueline Garonzik; Philosophe, Benjamin; Cameron, Andrew M.; Gurakar, Ahmet
• Is Part Of: ACG Case Reports Journal. Volume 8:Issue 5(2021)
• Page Start: e00582
• Publication Date: 2021-05-12
• DOI: 10.14309/crj.0000000000000582
• Languages: English
• ISSNs: 2326-3253

Abstract

ABSTRACT: Liver transplantation (LT) for patients with hepatitis D virus (HDV) and hepatitis B virus (HBV) coinfection is uncommon in the United States. Previous case reports described poor outcomes when hepatitis B surface antigen (HBsAg)-positive grafts are transplanted in HBV/HDV-coinfected recipients. However, LT from an HBsAg-negative/HBV-deoxyribonucleic acid–positive donor in an HBV/HDV-coinfected recipient has not been reported. We describe the clinical course and management of an HBV/HDV-coinfected recipient who had LT from an HBsAg-negative/HBV-deoxyribonucleic acid–positive deceased donor and was treated with high-dose hepatitis B immune globulin in combination with an oral tenofovir alafenamide.